Lauded for its ‘commitment to high ethical values’ ​​and ‘professional approach’, the team at Galicia Abogados S.C. is a strong choice for a range of transactional, regulatory and contentious life sciences matters. The 'reliable’ group, which is supported by the firm’s comprehensive full-service offering, is a key port of call for international pharmaceutical companies, medical device manufacturers, clinical trial organisations, think tanks and corporations in the food, beverage and tobacco sectors. Core areas of expertise include advising on government procurement, healthcare M&A and regulatory matters relating to the sale of medicines, medical devices and vaccines. Leadership is shared between ‘one-of-a-kind lawyer’ Bernardo Martínez Negrete; and Lisandro Herrera, noted for his ‘great professionalism and commitment to his clients’. Martínez Negrete majors on commercial, regulatory and financial matters and is known for his longstanding involvement in healthcare projects for pharmaceutical-sector clients. Herrera was promoted to partnership in January 2025 and specialises in healthcare regulation, public procurement processes, pharmaceutical regulation and regulatory compliance matters.

Noted for its ‘deep, well-founded opinions’ and ‘customised and highly effective solutions’, the ‘robust’ team at Hogan Lovells is equipped to advise on the gamut of life sciences mandates, taking in regulatory, transactional and contentious aspects. Core areas of expertise include the launch of new pharmaceutical, biotech, cosmetics and food products, advising on research and clinical studies, labelling and advertising issues, M&A transactions, and administrative litigation. The team’s capabilities extend to food safety and quality issues, product recalls, the handling of sensitive compliance matters involving controlled substances, advice concerning GMO products and anti-corruption compliance issues in the biotech industry. The practice is co-directed by Ernesto Algaba Reyes, who specialises in health law, regulatory compliance matters for the pharmaceutical and medical devices industries and consumer protection law. Co-leading alongside him is ‘exceptional professional’ Cecilia Stahlhut Espinosa, who is lauded for her ‘extensive experience in diverse regulatory matters’ and ‘excellent client management skills’ and deals with regulatory drug, digital health, biotech, alcohol and consumer product mandates.

Olivares is highly specialised in IP law in the pharmaceutical sector, and the group’s expertise extends to regulatory and contentious matters relating to the research, development and manufacture of pharmaceuticals, biotech products and agricultural goods. The team, lauded for its ‘deep understanding of the industry’, routinely handles patent term corrections and patent linkage; provides advice on marketing authorisations and approvals; and assists with the transfer of assets in the life science sector. Leadership is shared between ‘A+ life sciences expert’ Gustavo Alcocer, who also manages the firm’s corporate and commercial law group; Alejandro Luna, who majors on IP, regulatory and administrative litigation; Armando Arenas, who co-leads the firm’s litigation group and handles administrative actions related to IP matters; and Rommy Morales, who co-leads the firm’s patent group and specialises in patent prosecution and IP litigation. Additional names to note include associates Ingrid Ortiz and Karla Olvera; and Mauricio Sámano, who focuses on prosecuting chemical, biotechnological and pharmaceutical patent applications.

The group at Baker McKenzie Abogados, S.C. is well-versed in regulatory, transactional and contentious life sciences mandates and is routinely instructed by notable international players in the pharmaceutical and retail spaces. The team’s wider expertise takes in corporate, IP, tax, commercial and administrative litigation, antitrust and compliance law. Following the June 2024 departure of Christian López Silva, leadership of the practice is entrusted to senior associate Carla Calderón. Calderón specialises in advising on matters at the intersection of regulatory law, data privacy and IP, including those related to the manufacturing, distribution and commercialisation of medicines, medical devices, foods and beverages. Additional key contacts include patent practice lead Marina Hurtado Cruz; Guadalajara-based Roberto Macias Saltijeral, who majors on M&A transactions, corporate reorganisations, contractual law and matters of foreign investment; compliance specialist Jonathan Edward Adams; and the corporate and M&A-focused Erik Gutiérrez. All named lawyers are based in Mexico City unless otherwise stated. Roberto Cardona left the firm in October 2024.

Lauded for its ‘knowledge of the administrative branch and proceedings before the authorities’, the team at CMS Woodhouse Lorente Ludlow is regularly engaged to assist with regulatory challenges, litigation and M&A transactions in the life sciences space. The group’s client roster routinely features major pharmaceutical companies, private hospital corporations and multinational medical device manufacturers. The practice is directed by Mauricio Gómez, who specialises in advising clients on regulatory strategies concerning premarket clearance for drugs and medical devices and the classification of consumer products. Also noted are César Armando Lechuga Perezanta (corporate and M&A, project finance and real estate); and senior associate Manuel Ferrara, who deals with constitutional and administrative litigation.

The capabilities of the life sciences practice at Creel, García-Cuéllar, Aiza y Enríquez, S.C. take in M&A transactions, the provision of regulatory advice on pharmaceutical, healthcare, medical device and consumer products matters. The team has noted experience in clinical trials, litigation before administrative authorities, and the manufacturing, packaging and export of pharmaceutical products. A recent highlight saw the team advise Daesang Corporation on including one of their products as a natural flavouring additive under the Mexican legal and regulatory applicable framework. Leadership is shared between Leonel Pereznieto, whose broad practice encompasses M&A, compliance and insurance law; and counsel Guillermo Govela, who draws on experience acting as general legal counsel for Mexico’s Federal Ministry of Health and specialises in regulatory law affecting healthcare and consumer products.

The practice group at Solórzano Linaldi is well-placed to handle contentious matters in the life sciences sector, in addition to providing assistance on a range of advisory mandates that includes drug marketing authorisations and advertising strategies for drugs, medical devices and alcoholic beverages. Court appeals, including amparo actions and litigation involving regulatory challenges against COFEPRIS, are a core area of expertise for the team. Leadership is shared between name partners Guillermo Solórzano and Luis López Linaldi, and Solórzano specialises in regulatory issues affecting the pharmaceutical segment, patents and trademarks litigation and administrative litigation. López Linaldi handles health regulation, international trade, e-commerce, data protection, AML and dispute resolution. Additional key contacts include associates Eréndira Frías (IP and sanitary law disputes); and Alan Osorio Aragón (IP and administrative law).

IP firm Arochi & Lindner, SC offers legal advice to a breadth of life-science clients throughout the product life cycle, from trademark and patent prosecution, through registrations, licensing and collaboration agreements, to labelling, advertising and marketing. Key contacts include Heidi Lindner and of counsel Julio Copo Terrés.

Following Adrián del Paso‘s departure from Ibarra, del Paso y Gallego to co-found Assembla in March 2024, the new firm has become one to watch in the life sciences space. The team, which is lauded for its ‘practical and forward-looking attitude’, is a key port of call for clients in the pharmaceutical, chemicals, consumer goods and healthcare sectors seeking assistance with a range of regulatory and transactional mandates. Del Paso draws on extensive experience in life sciences, healthcare and environmental law matters, while counsels Mauricio Sandoval (environmental issues, administrative and constitutional litigation); and Mariana Carrión, who joined the team from Novartis in October 2024.

The practice at Garrigues was substantially bolstered by the office’s merger with local firm Sanchez Devanny, which was announced in July 2024 and was completed in February 2025. The combined group draws on experience advising domestic and multinational businesses on life science mandates, from the manufacturing stages through to the preparation of products for sale in Mexico or for export. The key names to note are José Alberto Campos- Vargas, Juan Luis Serrano and principal associate María Luisa Mendoza López.

Recently bolstered by its July 2024 absorption of González Calvillo, the Mexican team at Madrid-headquartered Pérez-Llorca is equipped to assist multinational and domestic clients with a range of regulatory mandates relating to pharmaceutical, food, drink and cosmetics products and medical devices. The group is well-versed in the management of authorisations issued by COFEPRIS, the review of research protocols and regulatory compliance review relating to the storage, distribution, labelling and importation of medicines and medical devices. Leadership of the team is split between counsels Enrique Muñoz Guízar and Carlos Fernando Castilla. Muñoz Guízar specialises in environmental law and regulatory matters relating to healthcare, natural resources, and consumer protection; Castilla handles dispute resolution, environmental and regulatory law. Senior associate Georgina Zavala handles environmental, life sciences and health-related regulatory matters.

SaúdeLaw is lauded for its ‘extensive knowledge of the health, pharma and life sciences ecosystems in Mexico’, the team of ‘excellent lawyers’ is well-placed to handle regulatory, transactional and contentious mandates for local and multinational industry players. Firm founder Christian López-Silva is the key contact, and he is the founding president of the Mexican Association of Pharmaceutical and Sanitary Regulation. López-Silva’s expertise spans, pharma, medical devices, cosmetics and clinical research services. Gerardo Calderón specialises in antitrust, competition and consumer law.